Cleared Traditional

K252533 - HemoSphere Alta Advanced Monitoring Pla...

Also marketed or referenced as:
ALTACR1 ALTASR1)

K252533 is an FDA 510(k) clearance for HemoSphere Alta Advanced Monitoring Pla..., manufactured by Edwards Lifesciences. The device is a Class 2 Cardiovascular device with product code DQK cleared through the Traditional 510(k) pathway after a 128-day FDA review.

K252533 · Edwards Lifesciences · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 2025
Decision
128d
Days
Class 2
Risk

K252533 is an FDA 510(k) clearance for the HemoSphere Alta Advanced Monitoring Platform (ALTAALL1. Classified as Computer, Diagnostic, Programmable (product code DQK), Class II - Special Controls.

Submitted by Edwards Lifesciences (Irvine, US). The FDA issued a Cleared decision on December 18, 2025 after a review of 128 days - within the typical 510(k) review window.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1425 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Cardiovascular review framework, consistent with the majority of Class II 510(k) submissions.

View all Edwards Lifesciences devices

FDA 510(k) Submission Details - K252533

510(k) Number K252533 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 12, 2025
Decision Date December 18, 2025
Days to Decision 128 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
3d slower than avg
Panel avg: 125d · This submission: 128d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DQK Device Classification - Class 2, Special Controls

Product Code DQK Computer, Diagnostic, Programmable
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1425
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DQK Computer, Diagnostic, Programmable

All 268
Devices cleared under the same product code (DQK) and FDA review panel - the closest regulatory comparables to K252533.
NorthStar™ Mapping System
K252164 · Imricor Medical Systems · Jan 2026
CARTO™ 3 EP Navigation System V9.0 with PIU Plus
K254085 · Biosense Webster, Inc. · Jan 2026
STAR Apollo™ Mapping System
K253733 · Rhythm AI, Ltd. · Dec 2025
DeepRhythmAI
K253141 · Medicalgorithmics S.A. · Dec 2025
Vektor Computational ECG Mapping System (vMap®)
K252429 · Vektor Medical, Inc. · Dec 2025
CoroFlow Cardiovascular System
K252238 · Coroventis Research AB · Oct 2025